HANSOH PHARMA(03692),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

03692 HANSOH PHARMA

Closed 01-14 16:08:06

42.940

+0.900

+2.14%

High43.600	Low42.440	Vol10.16M
Open43.460	D1 Closing42.040	Amplitude2.76%
Mkt Cap260.00B	Tradable Cap260.00B	Total Shares6.06B
T/O436.86M	T/O Rate0.17%	Tradable Shares6.06B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"03692","market":"HK","secType":"STK","nameCN":"HANSOH PHARMA","latestPrice":42.94,"timestamp":1768378086009,"preClose":42.04,"halted":0,"volume":10159889,"delay":0,"floatShares":6055000000,"shares":6055000000,"eps":0.8242340382513235,"marketStatus":"Closed","change":0.9,"latestTime":"01-14 16:08:06","open":43.46,"high":43.6,"low":42.44,"amount":436860580,"amplitude":0.027593,"askPrice":42.96,"askSize":26000,"bidPrice":42.94,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":0.8977696235371169,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":5,"adr":0,"listingDate":1560441600000,"exchange":"SEHK","adjPreClose":42.04,"dividendRate":0.008855,"openAndCloseTimeList":[[1768354200000,1768363200000],[1768366800000,1768377600000]],"volumeRatio":0.706441,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03692","defaultTab":"news","newsList":[{"id":"2603695625","title":"Hansoh Pharmaceutical Group  Stock Rallies 2.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2603695625","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603695625?lang=en_us&edition=fundamental","pubTime":"2026-01-14 16:32","pubTimestamp":1768379520,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. rose 2.1% to 42.94 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.6% to 26999.81.This was the stock's second consecutive day of gains.Hansoh Pharmaceutical Group Co. Ltd. closed 2.9% short of its 52-week high of HK$44.22, which the company achieved Dec. 12.Trading volume totaled 10.2 million shares, compared to the 50-day average of 8.7 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","03692","BK1583","BK1191"],"gpt_icon":0},{"id":"1190906700","title":"HK Stock Movement | HANSOH PHARMA (03692) Rises Over 4% Before Noon; Ameile® Gains Fifth Indication Approval; Adjuvant Therapy Research Published in The Lancet Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=1190906700","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190906700?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:45","pubTimestamp":1768275940,"startTime":"0","endTime":"0","summary":"HANSOH PHARMA (03692) rose more than 4% before noon. As of the time of writing, the stock was up 3.64%, trading at HK$42.12 with a turnover of HK$97.6223 million. On January 8, HANSOH PHARMA...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1589","03692","BK1583"],"gpt_icon":0},{"id":"2602976005","title":"China Approves Ameile Combination Therapy as First-Line Treatment for EGFR-Mutated NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2602976005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602976005?lang=en_us&edition=fundamental","pubTime":"2026-01-12 16:44","pubTimestamp":1768207442,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co., Ltd. announced that its drug Ameile  has received regulatory approval in China for a new indication. The newly approved use is Ameile in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer  whose tumors have EGFR exon 19 deletions or exon 21  mutations. This approval is supported by results from the Phase III AENEAS 2 study, which demonstrated a significant improvement in progression-free survival and objective response rate compared to monotherapy, with no new safety concerns. This marks the fifth approved indication for Ameile in China, enabling full-course treatment coverage for EGFR-mutated NSCLC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should no","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7BBC05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","03692","BK1589"],"gpt_icon":0},{"id":"2602711592","title":"Hansoh Pharmaceutical Group  Stock Sheds 2.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2602711592","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602711592?lang=en_us&edition=fundamental","pubTime":"2026-01-12 16:32","pubTimestamp":1768206720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. shed 2.3% to 40.64 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.4% to 26608.48.The stock's fall snapped a six-day winning streak.Hansoh Pharmaceutical Group Co. Ltd. closed 8.1% below its 52-week high of HK$44.22, which the company reached Dec. 12.Trading volume totaled 7.3 million shares, compared to the 50-day average of 8.8 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","BK1589","03692"],"gpt_icon":0},{"id":"2602853876","title":"Hansoh Pharmaceutical Group SEHK 3692 Valuation Check After Ameile First Line Lung Cancer Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2602853876","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602853876?lang=en_us&edition=fundamental","pubTime":"2026-01-10 17:31","pubTimestamp":1768037496,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group (SEHK:3692) has just received Chinese NMPA approval to expand lung cancer drug Ameile’s use as a first line option in combination therapy for specific EGFR mutated NSCLC patients.\nSee our latest analysis for Hansoh Pharmaceutical Group.\nThe Ameile update comes after a reshuffle of Hansoh Pharmaceutical Group’s board and committees in late December 2025. The latest 1-day share price return of 2.11% at HK$41.6 sits within a year-to-date share price return of 14.16%...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk-3692-valuation-check-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk-3692-valuation-check-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","DCF","BK1589","BK1191","03692"],"gpt_icon":0},{"id":"2601369315","title":"Hansoh Pharma Gets China Nod for Additional Indication of Lung Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369315","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369315?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:11","pubTimestamp":1767874289,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group  said an additional indication of Ameile was granted registration approval by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The additional indication is for use of the drug in combination with pemetrexed and platinum-based chemotherapy to treat adult patients with locally advanced or metastatic non-small cell lung cancer.This is the fifth indication of the drug which has been approved.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["03692","BK1583","BK1589","BK1191"],"gpt_icon":0},{"id":"1191152049","title":"HANSOH PHARMA (03692): Ameile® (Almonertinib Mesylate Tablets) Receives Fifth Indication Approval from NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1191152049","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191152049?lang=en_us&edition=fundamental","pubTime":"2026-01-08 17:50","pubTimestamp":1767865839,"startTime":"0","endTime":"0","summary":"HANSOH PHARMA (03692) announced that its innovative drug Ameile® (Almonertinib Mesylate Tablets) has obtained a drug registration certificate issued by China's National Medical Products...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","03692","BK1589"],"gpt_icon":0},{"id":"2601357483","title":"Hansoh Pharmaceutical Wins NMPA Approval for Fifth Ameile Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2601357483","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601357483?lang=en_us&edition=fundamental","pubTime":"2026-01-08 17:47","pubTimestamp":1767865664,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co. Ltd. has announced that its innovative drug Ameile  has received drug registration approval from the National Medical Products Administration  of China for a fifth indication. The new approval allows Ameile, in combination with pemetrexed and platinum-based chemotherapy, to be used as first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer  whose tumors have EGFR exon 19 deletions or exon 21  mutations. This regulatory milestone expands the therapeutic options for NSCLC patients with specific EGFR mutations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL174lT9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1191","03692","BK1583"],"gpt_icon":0},{"id":"2601125357","title":"Hansoh Pharmaceutical - Drug Registration Approval of the Fifth Indication of Ameile Granted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2601125357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601125357?lang=en_us&edition=fundamental","pubTime":"2026-01-08 17:47","pubTimestamp":1767865656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y818F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1191","03692","BK1589"],"gpt_icon":0},{"id":"2601113351","title":"Hansoh Pharmaceutical Group  Stock Climbs 1.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2601113351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601113351?lang=en_us&edition=fundamental","pubTime":"2026-01-08 16:32","pubTimestamp":1767861120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. rallied 1.7% to 40.74 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.2% to 26149.31.This was the stock's fifth consecutive day of gains.Hansoh Pharmaceutical Group Co. Ltd. closed 7.9% below its 52-week high of HK$44.22, which the company achieved Dec. 12.Trading volume totaled 8.5 million shares, compared to the 50-day average of 8.7 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1583","03692","BK1191"],"gpt_icon":0},{"id":"2601862873","title":"Hansoh Pharmaceutical Group  Stock Rises 3.8% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2601862873","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601862873?lang=en_us&edition=fundamental","pubTime":"2026-01-07 16:30","pubTimestamp":1767774600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. advanced 3.8% to 40.04 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.9% to 26458.95.This was the stock's fourth consecutive day of gains.Hansoh Pharmaceutical Group Co. Ltd. closed 9.5% below its 52-week high of HK$44.22, which the company achieved Dec. 12.Trading volume totaled 43.7 million shares, compared to the 50-day average of 8.0 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1589","BK1191","03692"],"gpt_icon":0},{"id":"2601982468","title":"Are Investors Undervaluing Hansoh Pharmaceutical Group Company Limited (HKG:3692) By 27%?","url":"https://stock-news.laohu8.com/highlight/detail?id=2601982468","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601982468?lang=en_us&edition=fundamental","pubTime":"2026-01-07 10:33","pubTimestamp":1767753186,"startTime":"0","endTime":"0","summary":"Key Insights Using the 2 Stage Free Cash Flow to Equity, Hansoh Pharmaceutical Group fair value estimate is HK$52.95...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/are-investors-undervaluing-hansoh-pharmaceutical-group-compa","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/are-investors-undervaluing-hansoh-pharmaceutical-group-compa","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4100","BK1583","BK4211","BK1191","ISBC","03692","DCF","TV","FCF","BK1589"],"gpt_icon":0},{"id":"2601060009","title":"Hansoh Pharmaceutical Group  Stock Climbs 4.5% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2601060009","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601060009?lang=en_us&edition=fundamental","pubTime":"2026-01-05 16:30","pubTimestamp":1767601800,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. rose 4.5% to 38.08 Hong Kong dollars , on what proved to be an all-around mediocre trading session for the Hong Kong stock market, with the Hang Seng Index remaining mostly flat at 26347.24.This was the stock's second consecutive day of gains.Hansoh Pharmaceutical Group Co. Ltd. closed 14% short of its 52-week high of HK$44.22, which the company reached Dec. 12.Trading volume totaled 8.6 million shares, compared to the 50-day average of 8.0 million shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1583","03692","BK1191"],"gpt_icon":0},{"id":"2595211788","title":"Hansoh Pharmaceutical Group  Stock Slips 1.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2595211788","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595211788?lang=en_us&edition=fundamental","pubTime":"2025-12-29 16:33","pubTimestamp":1766997180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. slipped 1.7% to 36.78 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.7% to 25635.23.This was the stock's fifth consecutive day of losses.Hansoh Pharmaceutical Group Co. Ltd. closed 17% short of its 52-week high of HK$44.22, which the company achieved Dec. 12.Trading volume totaled 5.2 million shares, compared to the 50-day average of 8.3 million shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","BK1589","03692"],"gpt_icon":0},{"id":"1104759270","title":"Stock Market Navigation: December 29, 2025 - Announcements and Trading Tips for Shanghai and Shenzhen Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1104759270","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104759270?lang=en_us&edition=fundamental","pubTime":"2025-12-29 07:31","pubTimestamp":1766964715,"startTime":"0","endTime":"0","summary":"Log in to the Sina Finance APP and search for [Disclosure] to view more evaluation ratings. Special Topic: Trading Tips. For stock trading, refer to the Golden Kirin Analyst Research Reports, which...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09880","BK1613","BK1583","BK1589","BK1191","BK1183","03692"],"gpt_icon":1},{"id":"2594522227","title":"Hansoh Pharmaceutical Group Files Director List with HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2594522227","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594522227?lang=en_us&edition=fundamental","pubTime":"2025-12-28 19:44","pubTimestamp":1766922297,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co. Ltd. has filed an updated list of directors and their roles with the Hong Kong Stock Exchange. The board comprises Executive Directors Ms. Zhong Huijuan , Ms. Sun Yuan, and Dr. Lyu Aifeng. Independent Non-executive Directors include Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao, and Mr. Yan Jia. The company has established five board committees. Ms. Zhong Huijuan serves as Chairlady of the Strategy and Development Committee and the Nomination Committee, and is a member of the Remuneration Committee. Dr. Lyu Aifeng is Chairman of the Environmental, Social and Governance Committee and a member of the Strategy and Development Committee. Mr. Lin Guoqiang sits on the Audit, Remuneration, and Nomination Committees. Mr. Chan Charles Sheung Wai is Chairman of the Audit Committee and a member of the Strategy and Development, Environmental, Social and Governance, and Nomination Committees. Ms. Yang Dongtao chairs the Remuneration Committee and is","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251228:nNDLbZR4r0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","03692","BK1589"],"gpt_icon":0},{"id":"2594246222","title":"Hansoh Pharmaceutical Appoints Yan Jia as Independent Director and Names New Company Secretaries","url":"https://stock-news.laohu8.com/highlight/detail?id=2594246222","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594246222?lang=en_us&edition=fundamental","pubTime":"2025-12-28 19:41","pubTimestamp":1766922083,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co. Ltd. has announced the appointment of Mr. Yan Jia as an independent non-executive director, effective December 26, 2025. The company also reported changes in the composition of its board committees and changes to its joint company secretary, authorized representative, and process agent.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251228:nNDL2MWkt3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1589","BK1191","03692"],"gpt_icon":0},{"id":"2594722240","title":"Hansoh Pharmaceutical Secures Exclusive License for SHR6508 from Hengrui","url":"https://stock-news.laohu8.com/highlight/detail?id=2594722240","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594722240?lang=en_us&edition=fundamental","pubTime":"2025-12-28 19:35","pubTimestamp":1766921757,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Company Limited announced that on December 26, 2025, it entered into a license agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd. Under the agreement, Hansoh Pharmaceutical obtained an exclusive license to develop, manufacture, and commercialize the product SHR6508 in China, excluding Hong Kong, Macau, and Taiwan. The agreement includes an upfront payment of RMB30 million, potential regulatory and commercialization milestone payments of up to RMB190 million, and tiered single-digit royalties on future net sales of the product. SHR6508 is described as an allosteric modulator of the calcium-sensing receptor  and is complementary to Hansoh Pharmaceutical’s existing nephrology portfolio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251228:nNDLbwBr2Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1583","03692","BK1191"],"gpt_icon":0},{"id":"1182974401","title":"HENGRUI PHARMA (600276.SH) Signs Exclusive Licensing Agreement with HANSOH PHARMA for SHR6508 Project","url":"https://stock-news.laohu8.com/highlight/detail?id=1182974401","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182974401?lang=en_us&edition=fundamental","pubTime":"2025-12-28 16:46","pubTimestamp":1766911585,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (600276.SH) announced that it has entered into an Exclusive Licensing Agreement with Hansoh Pharmaceutical Group Co., Ltd. (\"HANSOH PHARMA\"), granting HANSOH PHARMA a paid license for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2148510915.USD","BK0060","BK0183","LU1997244956.HKD","LU2097828474.EUR","LU2097828714.EUR","BK1589","LU2543165471.USD","600276","LU2328871848.SGD","LU1146622755.USD","LU1820825898.SGD","LU2097828631.EUR","LU1997245177.USD","BK0012","01276","BK0239","LU1023057109.AUD","LU1655091616.SGD","LU0405327148.USD","BK0028","LU1064130708.USD","LU2488822045.USD","LU1969619763.USD","03692","LU1328615791.USD","LU0359202008.SGD","BK1191","LU0359201885.HKD","LU1064131003.USD","LU2289578879.USD","LU0359201612.USD","LU2580892789.USD","BK0196","LU2580892862.HKD","LU0405327494.USD","LU1997245094.SGD","BK0188","LU1580142542.USD","LU2097828557.USD","LU2495084118.USD","BK1583","LU1781817850.SGD","LU2097828805.USD","LU1255011170.USD"],"gpt_icon":0},{"id":"2593420459","title":"Hansoh Pharmaceutical Group  Stock Falls 0.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2593420459","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593420459?lang=en_us&edition=fundamental","pubTime":"2025-12-24 16:32","pubTimestamp":1766565120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Hansoh Pharmaceutical Group Co. Ltd. slipped 0.7% to 37.42 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 25818.93.This was the stock's fourth consecutive day of losses.Hansoh Pharmaceutical Group Co. Ltd. closed 15% below its 52-week high of HK$44.22, which the company achieved Dec. 12.Trading volume totaled 1.9 million shares, compared to the 50-day average of 8.4 million shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1191","BK1583","BK1589"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0897},{"period":"1month","weight":-0.0223},{"period":"3month","weight":0.197},{"period":"6month","weight":0.2267},{"period":"1year","weight":1.6144},{"period":"ytd","weight":0.1652}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0336},{"period":"3month","weight":0.0362},{"period":"6month","weight":0.0959},{"period":"1year","weight":0.4225},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.011055},{"month":2,"riseRate":0.5,"avgChangeRate":0.00076},{"month":3,"riseRate":0.333333,"avgChangeRate":0.024785},{"month":4,"riseRate":0.5,"avgChangeRate":0.03201},{"month":5,"riseRate":0.666667,"avgChangeRate":0.019349},{"month":6,"riseRate":0.666667,"avgChangeRate":0.055622},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000332},{"month":8,"riseRate":0.714286,"avgChangeRate":0.01897},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.033021},{"month":10,"riseRate":0.142857,"avgChangeRate":0.001586},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063467},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016858}],"exchange":"SEHK","name":"HANSOH PHARMA","nameEN":"HANSOH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HANSOH PHARMA(03692),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HANSOH PHARMA(03692) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HANSOH PHARMA,03692,HANSOH PHARMA股票,HANSOH PHARMA股票老虎,HANSOH PHARMA股票老虎国际,HANSOH PHARMA行情,HANSOH PHARMA股票行情,HANSOH PHARMA股价,HANSOH PHARMA股市,HANSOH PHARMA股票价格,HANSOH PHARMA股票交易,HANSOH PHARMA股票购买,HANSOH PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HANSOH PHARMA(03692),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HANSOH PHARMA(03692) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}